JP2023523568A - ＡｃｔＲＩＩＢリガンドトラップ及びフェドラチニブを使用して貧血を治療するための方法 - Google Patents

ＡｃｔＲＩＩＢリガンドトラップ及びフェドラチニブを使用して貧血を治療するための方法 Download PDF

Info

Publication number
JP2023523568A
JP2023523568A JP2022562528A JP2022562528A JP2023523568A JP 2023523568 A JP2023523568 A JP 2023523568A JP 2022562528 A JP2022562528 A JP 2022562528A JP 2022562528 A JP2022562528 A JP 2022562528A JP 2023523568 A JP2023523568 A JP 2023523568A
Authority
JP
Japan
Prior art keywords
subject
ligand trap
actriib ligand
actriib
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022562528A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523568A5 (https=
JPWO2021211418A5 (https=
Inventor
ラーデム，アブデラーマン
リットランド，スティーブ
ティ バックストーム，ジェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2023523568A publication Critical patent/JP2023523568A/ja
Publication of JP2023523568A5 publication Critical patent/JP2023523568A5/ja
Publication of JPWO2021211418A5 publication Critical patent/JPWO2021211418A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2022562528A 2020-04-13 2021-04-12 ＡｃｔＲＩＩＢリガンドトラップ及びフェドラチニブを使用して貧血を治療するための方法 Pending JP2023523568A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063009400P 2020-04-13 2020-04-13
US63/009,400 2020-04-13
PCT/US2021/026816 WO2021211418A1 (en) 2020-04-13 2021-04-12 Methods for treating anemia using an actriib ligand trap and fedratinib

Publications (3)

Publication Number Publication Date
JP2023523568A true JP2023523568A (ja) 2023-06-06
JP2023523568A5 JP2023523568A5 (https=) 2024-04-05
JPWO2021211418A5 JPWO2021211418A5 (https=) 2024-04-05

Family

ID=78085002

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022562528A Pending JP2023523568A (ja) 2020-04-13 2021-04-12 ＡｃｔＲＩＩＢリガンドトラップ及びフェドラチニブを使用して貧血を治療するための方法

Country Status (10)

Country Link
US (1) US20230181690A1 (https=)
EP (1) EP4135736A4 (https=)
JP (1) JP2023523568A (https=)
KR (1) KR20230003502A (https=)
CN (1) CN115427056A (https=)
AU (1) AU2021256419A1 (https=)
BR (1) BR112022020628A2 (https=)
IL (1) IL297258A (https=)
MX (1) MX2022012610A (https=)
WO (1) WO2021211418A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017537921A (ja) * 2014-12-03 2017-12-21 アクセルロン ファーマ， インコーポレイテッド 骨髄異形成症候群および鉄芽球性貧血を処置するための方法
JP2019522022A (ja) * 2016-07-27 2019-08-08 アクセルロン ファーマ， インコーポレイテッド 骨髄線維症を処置するための方法および組成物
WO2020068754A1 (en) * 2018-09-25 2020-04-02 Impact Biomedicines, Inc. Methods of treating myeloproliferative disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018501307A (ja) * 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
PT3286206T (pt) * 2015-04-22 2021-04-01 Biogen Ma Inc Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular
CN107847562A (zh) * 2015-05-13 2018-03-27 细胞基因公司 使用 ACTRII 配体陷阱治疗 β‑地中海贫血
WO2018053142A2 (en) * 2016-09-14 2018-03-22 President And Fellows Of Harvard College Methods and compositions for modulating erythropoiesis
JOP20190085A1 (ar) * 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
HRP20241477T1 (hr) * 2017-06-14 2025-01-03 Celgene Corporation Postupci liječenja mijeloproliferativne neoplazme povezane s mijelofibrozom i anemijom
KR20210047308A (ko) * 2018-08-21 2021-04-29 시에라 온코로지, 인코퍼레이티드 골수섬유증을 치료하는 혈소판 수-불특정 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017537921A (ja) * 2014-12-03 2017-12-21 アクセルロン ファーマ， インコーポレイテッド 骨髄異形成症候群および鉄芽球性貧血を処置するための方法
JP2019522022A (ja) * 2016-07-27 2019-08-08 アクセルロン ファーマ， インコーポレイテッド 骨髄線維症を処置するための方法および組成物
WO2020068754A1 (en) * 2018-09-25 2020-04-02 Impact Biomedicines, Inc. Methods of treating myeloproliferative disorders

Also Published As

Publication number Publication date
MX2022012610A (es) 2022-11-07
EP4135736A1 (en) 2023-02-22
AU2021256419A1 (en) 2022-10-20
KR20230003502A (ko) 2023-01-06
IL297258A (en) 2022-12-01
WO2021211418A1 (en) 2021-10-21
EP4135736A4 (en) 2024-06-26
CN115427056A (zh) 2022-12-02
US20230181690A1 (en) 2023-06-15
BR112022020628A2 (pt) 2022-11-29

Similar Documents

Publication Publication Date Title
JP6976859B2 (ja) ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療
JP7496686B2 (ja) 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法
ES2946160T3 (es) Antagonistas de activina-ActRII y usos para tratar síndrome mielodisplásico
JP2017519009A (ja) 製剤化された受容体ポリペプチドおよび関連する方法
US20200024344A1 (en) Compositions and methods for treating immune thrombocytopenia
ES2575160T3 (es) Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G
US20240043517A1 (en) Anti-gdf15 antibody and a dosage regimen for the treatment of cancer
JP2003530867A (ja) トロンボポエチン受容体モジュレートペプチド
JP2023523568A (ja) ＡｃｔＲＩＩＢリガンドトラップ及びフェドラチニブを使用して貧血を治療するための方法
CN104995207B (zh) β整联蛋白-G蛋白α亚基结合相互作用的抑制剂
US20230210827A1 (en) Methods and compositions for treating anemia using actriib ligand traps and mtor inhibitors
JP2025509401A (ja) 頭頸部がん治療のための三重複合薬物投与療法
HK40077393A (en) Methods for treating anemia using an actriib ligand trap and fedratinib
RU2837724C2 (ru) Способ комбинаторной терапии при лечении миелопролиферативных новообразований конъюгатом дифтерийного токсина с интерлейкином-3 человека в комбинации с другими агентами

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240326

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250325

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250924

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260106